Yang Meiqin, Zhai Zhensheng, Guo Shuang, Li Xiaoxi, Zhu Yongxia, Wang Yue
Department of Gynecology and Obstetrics, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou 450000, Henan, People's Republic of China.
Department of Hepato-Biliary-Pancreatic Surgery, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzho 450000, Henan, People's Republic of China.
Onco Targets Ther. 2019 Jun 7;12:4469-4480. doi: 10.2147/OTT.S205622. eCollection 2019.
Long noncoding RNAs (lncRNAs) have been reported to play a key role in the development and progression of human malignancies. FLJ33360 is an lncRNA with unknown functions. This study was designed to determine the clinical significance and mechanism of FLJ33360 in ovarian cancer.
The clinical significance of FLJ33360 in ovarian cancer was determined using the Gene Expression Profiling Interactive Analysis (GEPIA) database, Kaplan-Meier Plotter database, quantitative reverse transcription polymerase chain reaction (qRT-PCR) and statistical analysis. The regulatory relationships between FLJ33360 and miR-30b-3p were explored through bioinformatics, the Gene Expression Omnibus (GEO) database, the ArrayExpress database and meta-analysis. The possible pathways were predicted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. In addition, the key target genes were identified using a protein-protein interaction (PPI) network, the Cancer Genome Atlas (TCGA) database, and correlation analysis.
FLJ33360 expression was significantly downregulated in ovarian cancer tissue (=0.0011) and was closely associated with International Federation of Gynecology and Obstetrics (FIGO) stage (=0.027) and recurrence (=0.002). FLJ33360 may have potential value in detecting ovarian cancer (area under the curve =0.793). Function analysis demonstrated that FLJ33360 can act as a molecular sponge of miR-30b-3p to regulate the expression of target genes that are mainly involved in positive regulation of smooth muscle cell migration, the unsaturated fatty acid metabolic process, and positive regulation of the epithelial to mesenchymal transition. Among these target genes, BCL2 is the hub gene.
FLJ33360 is a potential biomarker for early diagnosis and prognostic assessment in ovarian cancer and may regulate the expression of genes by sponging miR-30b-3p and thus participate in the development of ovarian cancer.
长链非编码RNA（lncRNAs）已被报道在人类恶性肿瘤的发生和发展中起关键作用。FLJ33360是一种功能未知的lncRNA。本研究旨在确定FLJ33360在卵巢癌中的临床意义及作用机制。
利用基因表达谱交互式分析（GEPIA）数据库、Kaplan-Meier Plotter数据库、定量逆转录聚合酶链反应（qRT-PCR）及统计分析来确定FLJ33360在卵巢癌中的临床意义。通过生物信息学、基因表达综合数据库（GEO）、ArrayExpress数据库及荟萃分析探索FLJ33360与miR-30b-3p之间的调控关系。使用基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析预测可能的信号通路。此外，利用蛋白质-蛋白质相互作用（PPI）网络、癌症基因组图谱（TCGA）数据库及相关性分析鉴定关键靶基因。
FLJ33360在卵巢癌组织中的表达显著下调（P = 0.0011），且与国际妇产科联盟（FIGO）分期（P = 0.027）及复发（P = 0.002）密切相关。FLJ33360在检测卵巢癌方面可能具有潜在价值（曲线下面积 = 0.793）。功能分析表明，FLJ33360可作为miR-30b-3p的分子海绵，调控主要参与平滑肌细胞迁移的正向调控、不饱和脂肪酸代谢过程及上皮-间质转化正向调控的靶基因表达。在这些靶基因中，BCL2是核心基因。
FLJ33360是卵巢癌早期诊断和预后评估的潜在生物标志物，可能通过吸附miR-30b-3p来调控基因表达，从而参与卵巢癌的发生发展。
